Literature DB >> 20595469

Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient.

Patricia Barragán1, Rogelio López-Velez, Montserrat Olmo, Daniel Podzamczer.   

Abstract

Visceral leishmaniasis is an opportunistic infection that affects human immunodeficiency virus-infected persons in leishmaniasis-endemic areas. The standard treatment may not be effective and relapses are common. We report the case of a human immunodeficiency virus-1-infected patient who had several relapses of visceral leishmaniasis after treatment with standard therapies and responded to a combined therapy.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20595469      PMCID： PMC2912567          DOI： 10.4269/ajtmh.2010.09-0594

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN： 0002-9637            Impact factor:   2.345


  20 in total

1.  Drug resistance in Indian visceral leishmaniasis.

Authors:  S Sundar
Journal:  Trop Med Int Health       Date:  2001-11       Impact factor: 2.622

2.  Maintenance itraconazole for visceral leishmaniasis in HIV infection.

Authors:  A Lafeuillade; P Chaffanjon; E Delbeke; R Quilichini
Journal:  Am J Med       Date:  1992-04       Impact factor: 4.965

3.  Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy.

Authors:  Rafael de La Rosa; Juan A Pineda; Juan Delgado; Juan Macías; Francisco Morillas; José A Mira; Armando Sánchez-Quijano; Manuel Leal; Eduardo Lissen
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

4.  Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate.

Authors:  C N Chunge; J Owate; H O Pamba; L Donno
Journal:  Trans R Soc Trop Med Hyg       Date:  1990 Mar-Apr       Impact factor: 2.184

5.  A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis.

Authors:  C P Thakur; T P Kanyok; A K Pandey; G P Sinha; A E Zaniewski; H H Houlihan; P Olliaro
Journal:  Trans R Soc Trop Med Hyg       Date:  2000 Jul-Aug       Impact factor: 2.184

6.  Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin)-antimonial combinations, a pilot study in Bihar, India.

Authors:  C P Thakur; P Olliaro; S Gothoskar; S Bhowmick; B K Choudhury; S Prasad; M Kumar; B B Verma
Journal:  Trans R Soc Trop Med Hyg       Date:  1992 Nov-Dec       Impact factor: 2.184

7.  Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone.

Authors:  J Seaman; D Pryce; H E Sondorp; A Moody; A D Bryceson; R N Davidson
Journal:  J Infect Dis       Date:  1993-09       Impact factor: 5.226

Review 8.  Paromomycin.

Authors:  Robert N Davidson; Margriet den Boer; Koert Ritmeijer
Journal:  Trans R Soc Trop Med Hyg       Date:  2008-10-23       Impact factor: 2.184

Review 9.  [Multiple digestive involvement in visceral leishmaniasis in a patient with HIV infection: favourable course with itraconazole].

Authors:  D Béchade; L Seurat; G Discamps; P H Tanière; F Du Bourguet
Journal:  Rev Med Interne       Date:  1996       Impact factor: 0.728

10.  Aminosidine plus sodium stibogluconate for the treatment of Indian kala-azar: a randomized dose-finding clinical trial.

Authors:  C P Thakur; S Bhowmick; L Dolfi; P Olliaro
Journal:  Trans R Soc Trop Med Hyg       Date:  1995 Mar-Apr       Impact factor: 2.184
View more
  3 in total

Review 1.  Visceral leishmaniasis and HIV coinfection in the Mediterranean region.

Authors:  Begoña Monge-Maillo; Francesca F Norman; Israel Cruz; Jorge Alvar; Rogelio López-Vélez
Journal:  PLoS Negl Trop Dis       Date:  2014-08-21

Review 2.  A screen-and-treat strategy targeting visceral leishmaniasis in HIV-infected individuals in endemic East African countries: the way forward?

Authors:  Johan van Griensven; Ermias Diro; Rogelio Lopez-Velez; Koert Ritmeijer; Marleen Boelaert; Ed E Zijlstra; Asrat Hailu; Lutgarde Lynen
Journal:  PLoS Negl Trop Dis       Date:  2014-08-07

3.  Immucillins ImmA and ImmH Are Effective and Non-toxic in the Treatment of Experimental Visceral Leishmaniasis.

Authors:  Elisangela Oliveira Freitas; Dirlei Nico; Marcus Vinícius Alves-Silva; Alexandre Morrot; Keith Clinch; Gary B Evans; Peter C Tyler; Vern L Schramm; Clarisa B Palatnik-de-Sousa
Journal:  PLoS Negl Trop Dis       Date:  2015-12-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.